|
|
|
|
Clinicopathologic Characteristics of Hepatocellular Carcinoma with Bile Duct Invasion
_ Clinicopathologic Characteristics of Hepatocellular Carcinoma with Bile Duct Invasion.
|
|
|
Wife's cancer diagnosis brings outpouring of help for couple
WAYNE, Ind.-- The warmth felt in the hands -- and hearts -- of two people chatting over cups of coffee hasn't been replaced by high-tech e-mails, text messages and cell phones.The coffee connection has moved some from neighbor to friend,...
|
|
|
Navigating The Shoals Of Breast Cancer
In the early 1990s, two oncologists troubled by how frustrated and confused their newly-diagnosed breast cancer patients felt decided to comprehensively address their lists of unanswered questions.The doctors teamed up to publish the...
|
|
|
Exams, good habits may detect breast cancer early
What is breast cancer?A.Breast cancer is a type of cancer in which cells in the breast tissue divide and grow without the normal control. There are two main types of breast cancer: ductal carcinoma and lobular carcinoma.
|
|
|
Dilemmas in the treatment of urothelial cancers of the prostate
Walsh DL et al.- Prostatic urothelial carcinoma is often under appreciated and not well understood. Malignant involvement of different anatomic locations of the prostate (i.e., mucosa, ducts, acini, and stroma) influence not...
|
|
|
::: Thallion's TLN-4601 inhibits mutated K-Ras signaling in cancer cells
- Thallion Pharmaceuticals Inc.(TSX: TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer cells. The research was conducted in the...
|
|
|
Thallions TLN-4601 inhibits mutated K-RAS signaling in cancer cells
Thallion Pharmaceuticals Inc.announces that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer cells. The research was conducted in the laboratories of Drs.
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
MONTREAL, QUEBEC--(Oct.24, 2008) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer cells. The...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
Thallion Pharmaceuticals Inc.(TSX: TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer cells. The research was conducted in the...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells More News related to TLN More News related to Press Releases MONTREAL, QUEBEC -- (MARKET WIRE) -- 10/24/08 -- Thallion Pharmaceuticals Inc.(TSX: TLN) today announced...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
0 MONTREAL (Marketwire) - Thallion Pharmaceuticals Inc.(TSX:TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer cells. The research was...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
(Marketwire via COMTEX News Network) -- Thallion Pharmaceuticals Inc.(TSX:TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer cells. The...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
MONTREAL, QUEBEC, October 24 / MARKET WIRE/ -- Thallion Pharmaceuticals Inc.(TSX: TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
Thallion Pharmaceuticals Inc.(TSX: TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer cells. The research was conducted in the...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
'These results demonstrate that TLN-4601 inhibits the growth of mutated K-Ras expressing cancer cells,' said Lloyd M.Segal, Chief Executive Officer of Thallion. 'A targeted cancer therapy that impacts K-Ras would address a significant...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
MONTREAL, QUEBEC--(Marketwire - Oct.24, 2008) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
ONTREAL, QUEBEC, October 24 / MARKET WIRE/ -- Thallion Pharmaceuticals Inc.(TSX: TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer cells...
|
|
|
Thallion Pharmaceuticals Inc.: Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
MONTREAL, QUEBEC--(Marketwire - Oct.24, 2008) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
MONTREAL, QUEBEC--(Marketwire - Oct.24, 2008) - Thallion Pharmaceuticals Inc. (TSX:TLN - News) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
-- Thallion Pharmaceuticals Inc.(Toronto:TLN.TO - News) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer cells. The research was conducted...
|
|
|
Thallion's TLN-4601 Inhibits Mutated K-Ras Signaling in Cancer Cells
MONTREAL, QUEBEC--(Marketwire - Oct.24, 2008) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced that data presented by collaborators demonstrated TLN-4601 inhibits proliferation and signaling of mutated K-Ras expressing cancer...
|
|
|
Men get breast cancer?
Male breast cancer is a disease in which malignant (cancer) cells form in the tissues of the breast.Breast cancer may occur in men. Men at any age may develop breast cancer, but it is usually detected (found) in men between 60 and 70...
|
|
|
Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous
1 Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan 2 Department of Cancer Survey, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan 3 Department of...
|
|
|
Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous
Development of ductal carcinoma of the pancreas during follow-up of branch duct...Uehara et al. 57: 1561-1565 To view this item, select one of the options below: Login for journal subscribers User Name Password Remember my...
|
|
|
Branch intraductal papillary mucinous neoplasms: just the tip of the iceberg?
Department of Surgery, University of Heidelberg, Germany Correspondence to:Professor Markus W Bchler, Department of Surgery, University of Heidelberg, INF 110, D-69120 Heidelberg, Germany; markus.buechler@med.uni-heidelberg.de The first 150...
|
